Dendritic Cell-Targeted Liposomes for Cancer Immunotherapy via Inhibition of Aryl Hydrocarbon Receptor
Researchers at the Institute of Biomedical Sciences have discovered a novel approach to cancer immunotherapy using dendritic cell-targeted liposomes. The study, published in the Journal of Nanobiotechnology, reveals that inhibiting the aryl hydrocarbon receptor (AhR) in dendritic cells enhances the production of IL-12 and IFN-g, promoting tumor-killing activity. This breakthrough has significant implications for the development of more effective cancer treatments.
Key Takeaways:
- The study identified a CD11c-targeting peptide (SP65) with high specificity for dendritic cells using phage display.
- SP65-functionalized liposomes showed enhanced drug uptake and selectivity for dendritic cells in vitro and in vivo.
- Incorporating the AhR inhibitor CH223191, the researchers developed SP65-lipo-CH, which promoted IL-12 secretion in dendritic cells.
- Co-culturing natural killer cells with SP65-lipo-CH-pretreated dendritic cells increased IFN-g production and tumor-killing activity.
- In MC38 and metastatic LLC mouse models, SP65-lipo-CH alone suppressed tumor growth and prolonged survival.
- Dendritic cell-targeted liposomes represent a promising strategy for cancer immunotherapy.
- Specific interaction between SP65 and CD11c transports CH223191 to dendritic cells, inhibiting AhR function.
- Inhibition of AhR promotes IL-12 and IFN-g production in dendritic cells and natural killer cells, respectively.
- The study provides a novel approach to targeting dendritic cells for cancer therapy.
Statistics:
- 23(1):683 is the journal volume and page number of the study.
- 115 is the zip code of the Institute of Biomedical Sciences in Taipei, Taiwan.
- 2025 is the year the study was published.
- 4 Crinan St, London N1 9XW, England is the address of BioMed Central.
- 28 is the day of the month the news article was published.
Sources:
- "Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor" (Journal of Nanobiotechnology, 2025;23(1):683)
- Chen-Yun Yeh, et al. (Institute of Biomedical Sciences, Academia Sinica)
- BioMed Central (www.biomedcentral.com)
- Journal of Nanobiotechnology (www.jnanobiotechnology.com)